Novavax, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020; filed March 1, 2021. This is an annual report, not a standalone Q4 report. Novavax is a clinical-stage biotechnology company focused on recombinant-protein vaccines and its Matrix-M adjuvant. Its lead priorities were COVID-19 vaccine candidate NVX-CoV2373 and influenza candidate NanoFlu; no vaccine had yet received regulatory approval.
Financial performance and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | $475.6 million | $18.7 million |
| Research and development expense | $747.0 million | $113.8 million |
| General and administrative expense | $145.3 million | $34.4 million |
| Operating loss | $416.7 million | $120.6 million |
| Net loss | $418.3 million; $7.27 per share | $132.7 million; $5.51 per share |
| Net cash used in operating activities | $42.5 million | $136.6 million |
- Revenue was primarily government and grant funding for NVX-CoV2373 development and manufacturing, rather than product sales. Government-contract revenue was $217.2 million; grants and other revenue were $258.4 million. The latter included a $20.0 million Takeda development milestone.
- Operating expenses substantially exceeded revenue: operating loss was about 87.6% of revenue and net loss about 87.9%. Gross margin is not meaningful because the company had no commercial vaccine sales.
- At year-end, cash and cash equivalents were $553.4 million, marketable securities $157.6 million, and restricted cash $95.3 million, totaling $806.4 million. Cash, cash equivalents and restricted cash at year-end were $648.7 million, versus $82.2 million in 2019.
- Current assets were $1.248 billion and current liabilities $579.7 million; working capital was $668.5 million. Deferred revenue was $273.2 million.
- Operating cash use declined year over year, aided by funding receipts and payment timing; it does not indicate operating profitability. Investing cash outflow was $377.8 million, including the Praha Vaccines acquisition and capital spending. Financing provided $984.8 million, chiefly from equity issuances.
- Debt included $325 million principal of 3.75% convertible notes due February 2023; carrying value was $322.0 million. Finance lease liabilities totaled $145.9 million. Total disclosed contractual obligations were $1.021 billion, including $420.2 million of purchase commitments and $103.1 million related to a facility lease not yet commenced.
- Stockholders’ equity was $627.2 million, compared with a deficit of $186.0 million at year-end 2019. The company sold common and preferred stock during 2020; preferred shares converted into common stock. Shares outstanding were approximately 71.0 million at December 31, 2020.
Material changes and notable developments
- Revenue rose by $456.9 million from 2019, principally from OWS and CEPI funding. At the same time, R&D expense increased by $633.2 million, primarily due to NVX-CoV2373 clinical, manufacturing and supply-chain work.
- Net loss increased by $285.6 million. A major unusual R&D charge was $245.9 million for right-of-use assets under manufacturing supply agreements, expensed because they had no alternative future use.
- Novavax acquired Praha Vaccines in May 2020 for approximately $167 million, adding a Czech manufacturing facility. Capital expenditures increased to $54.6 million from $1.9 million.
- Equity financing materially strengthened liquidity but increased the share base: 2020 net proceeds from common stock were approximately $875.6 million, with an additional $199.8 million from preferred stock.
Outlook, commentary and risks
- Management expected 2021 revenue and R&D and G&A expenses to increase significantly, driven by NVX-CoV2373 funding, development and potential commercialization. Product revenue depended on regulatory authorization and delivery; management did not provide quantified earnings guidance.
- At filing, management projected global NVX-CoV2373 manufacturing capacity above two billion annualized doses at full capacity, expected in mid-2021. Supply agreements then covered approximately 200 million doses for delivery through 2021 and the first half of 2022, conditional on approval and manufacturing execution.
- Subsequent to year-end, the company reported interim efficacy of 89.3% in its UK Phase 3 trial and 60% among HIV-negative participants in its South Africa Phase 2b trial. These were interim clinical findings, not audited financial results; the U.S./Mexico Phase 3 trial was ongoing. The filing described regulatory submissions and authorizations as anticipated, not achieved.
- Funding support included up to $1.75 billion under OWS, up to $45.7 million under the DoD contract, and up to $399.5 million from CEPI. Funding is conditional; termination, unmet milestones, approval delays, or supply shortfalls could affect receipts. Customer advances may need to be refunded if delivery obligations are not met.
- Key risks include clinical and regulatory uncertainty; the ability to scale, qualify and coordinate a complex third-party manufacturing network; competition from already-authorized COVID-19 vaccines; variant-related efficacy; and ongoing cash needs, despite year-end liquidity. The company also cited potential dilution, volatile share price, supply and raw-material constraints, and risks from international operations.
- Management reported effective disclosure controls and internal control over financial reporting; the assessment excluded the acquired Novavax CZ business. Ernst & Young issued unqualified opinions on the financial statements and internal controls, with Novavax CZ excluded from the auditor’s internal-control audit.
Important facts for investors to verify
- Regulatory status and final, complete efficacy and safety results for NVX-CoV2373, including performance against variants and the status of U.S. and international filings.
- Whether projected manufacturing capacity and partner output translate into approved, releasable doses, and whether delivery commitments can be met on schedule.
- How much of reported revenue and liquidity depends on conditional government and grant funding, deferred customer advances, and restricted cash.
- Cash burn, capital spending, purchase commitments, finance leases and the ability to service or refinance the 2023 convertible notes.
- Actual economics of supply and licensing arrangements, including partner royalties, cost-sharing, pricing, potential refunds, and revenue recognition upon vaccine deliveries.
- Ongoing dilution and equity compensation: share issuance, stock-based compensation expense of $128.0 million in 2020, and subsequent financing after year-end.
- Progress of NanoFlu and other pipeline programs, and the impact of continued COVID-19 investment on their funding and development.